Expanding Access to High KDPI Kidney Transplant for Recipients Aged 60 y and Older: Cost Utility and Survival.


Journal

Transplantation direct
ISSN: 2373-8731
Titre abrégé: Transplant Direct
Pays: United States
ID NLM: 101651609

Informations de publication

Date de publication:
Jun 2024
Historique:
received: 28 11 2023
revised: 05 02 2024
accepted: 21 02 2024
medline: 17 5 2024
pubmed: 17 5 2024
entrez: 17 5 2024
Statut: epublish

Résumé

Modern organ allocation systems are tasked with equitably maximizing the utility of transplanted organs. Increasing the use of deceased donor organs at risk of discard may be a cost-effective strategy to improve overall transplant benefit. We determined the survival implications and cost utility of increasing the use of marginal kidneys in an older adult Canadian population of patients with end-stage kidney disease. We constructed a cost-utility model with microsimulation from the perspective of the Canadian single-payer health system for incident transplant waitlisted patients aged 60 y and older. A kidney donor profile index score of ≥86 was considered a marginal kidney. Donor- and recipient-level characteristics encompassed in the kidney donor profile index and estimated posttransplant survival scores were used to derive survival posttransplant. Patients were followed up for 10 y from the date of waitlist initiation. Our analysis compared the routine use of marginal kidneys (marginal kidney scenario) with the current practice of limited use (status quo scenario). The 10-y mean cost and quality-adjusted life-years per patient in the marginal kidney scenario were estimated at $379 485.33 (SD: $156 872.49) and 4.77 (SD: 1.87). In the status quo scenario, the mean cost and quality-adjusted life-years per patient were $402 937.68 (SD: $168 508.85) and 4.37 (SD: 1.87); thus, the intervention was considered dominant. At 10 y, 62.8% and 57.0% of the respective cohorts in the marginal kidney and status quo scenarios remained alive. Increasing the use of marginal kidneys in patients with end-stage kidney disease aged 60 y and older may offer cost savings, improved quality of life, and greater patient survival in comparison with usual care.

Sections du résumé

Background UNASSIGNED
Modern organ allocation systems are tasked with equitably maximizing the utility of transplanted organs. Increasing the use of deceased donor organs at risk of discard may be a cost-effective strategy to improve overall transplant benefit. We determined the survival implications and cost utility of increasing the use of marginal kidneys in an older adult Canadian population of patients with end-stage kidney disease.
Methods UNASSIGNED
We constructed a cost-utility model with microsimulation from the perspective of the Canadian single-payer health system for incident transplant waitlisted patients aged 60 y and older. A kidney donor profile index score of ≥86 was considered a marginal kidney. Donor- and recipient-level characteristics encompassed in the kidney donor profile index and estimated posttransplant survival scores were used to derive survival posttransplant. Patients were followed up for 10 y from the date of waitlist initiation. Our analysis compared the routine use of marginal kidneys (marginal kidney scenario) with the current practice of limited use (status quo scenario).
Results UNASSIGNED
The 10-y mean cost and quality-adjusted life-years per patient in the marginal kidney scenario were estimated at $379 485.33 (SD: $156 872.49) and 4.77 (SD: 1.87). In the status quo scenario, the mean cost and quality-adjusted life-years per patient were $402 937.68 (SD: $168 508.85) and 4.37 (SD: 1.87); thus, the intervention was considered dominant. At 10 y, 62.8% and 57.0% of the respective cohorts in the marginal kidney and status quo scenarios remained alive.
Conclusions UNASSIGNED
Increasing the use of marginal kidneys in patients with end-stage kidney disease aged 60 y and older may offer cost savings, improved quality of life, and greater patient survival in comparison with usual care.

Identifiants

pubmed: 38757046
doi: 10.1097/TXD.0000000000001629
pii: TXD-2023-0203
pmc: PMC11098249
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e1629

Informations de copyright

Copyright © 2024 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest.

Auteurs

Ryan J Bamforth (RJ)

Chronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, MB, Canada.

Aaron Trachtenberg (A)

Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.
Transplant Manitoba Adult Kidney Program, Winnipeg, MB, Canada.

Julie Ho (J)

Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.
Transplant Manitoba Adult Kidney Program, Winnipeg, MB, Canada.

Chris Wiebe (C)

Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.
Transplant Manitoba Adult Kidney Program, Winnipeg, MB, Canada.

Thomas W Ferguson (TW)

Chronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, MB, Canada.

Claudio Rigatto (C)

Chronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, MB, Canada.
Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.

Evelyn Forget (E)

Department of Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada.

Nancy Dodd (N)

Transplant Manitoba Adult Kidney Program, Winnipeg, MB, Canada.

Navdeep Tangri (N)

Chronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, MB, Canada.
Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada.

Classifications MeSH